This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Ferric oxide is an ingredient used in a number of skin protecting products.

Brand Names
Aveeno Anti-itch Reformulated Jun 2007, Baby Anti Monkey Butt Diaper Rash Powder, Caladryl, Calazime Skin Protectant
Generic Name
Ferric oxide
DrugBank Accession Number
DB11576
Background

Iron(III) oxide or ferric oxide is the inorganic compound with the formula Fe2O3. It is one of the three main oxides of iron, the other two being iron(II) oxide (FeO) the rarer form, and iron(II,III) oxide (Fe3O4) which naturally as magnetite.

Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 159.687
Monoisotopic: 159.854616
Chemical Formula
Fe2O3
Synonyms
  • Anhydrous Ferric Oxide
  • Anhydrous Iron (III) Oxide
  • Blood stone
  • Eisen(III)-oxid
  • Eisentrioxid
  • Ferric oxide red
  • Hematite
  • Indian red
  • Iron oxide
  • Iron oxide red
  • Iron oxide, red
  • Iron trioxide
  • Iron(III) oxide
External IDs
  • 215-168-2
  • E 172 Red

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Alendronic acidFerric oxide can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
AsenapineAsenapine can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium PhosphateFerric oxide can cause a decrease in the absorption of Calcium Phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium phosphate dihydrateFerric oxide can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
CarbidopaFerric oxide can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
CefdinirFerric oxide can cause a decrease in the absorption of Cefdinir resulting in a reduced serum concentration and potentially a decrease in efficacy.
CimetidineCimetidine can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CinoxacinFerric oxide can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiprofloxacinFerric oxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Clodronic acidFerric oxide can cause a decrease in the absorption of Clodronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Anti Monkey Butt Diaper RashFerric oxide (0.001 g/1g) + Zinc oxide (0.139 g/1g)CreamTopicalDse Healthcare Solutions, Llc.2010-05-012012-04-16US flag
Anti Monkey Butt Diaper RashFerric oxide (0.001 g/1g) + Zinc oxide (0.139 g/1g)CreamTopicalDse Healthcare Solutions, Llc.2012-04-182014-10-14US flag
Au Kah Chuen FugicalFerric oxide (0.05 g/100g) + Diphenhydramine hydrochloride (2 g/100g) + Zinc oxide (9.95 g/100g)CreamTopicalZhejiang Dingtai Pharmaceutical Co., Ltd2019-06-10Not applicableUS flag
Aveeno Anti Itch ConcentratedFerric oxide (0.6 mg/1mL) + Pramoxine hydrochloride (10 mg/1mL) + Zinc oxide (29.4 mg/1mL)LotionTopicalJohnson & Johnson Consumer Inc.2012-11-072023-12-01US flag
Aveeno Anti-Itch ConcentratedFerric oxide (0.6 mg/1mL) + Pramoxine hydrochloride (10 mg/1mL) + Zinc oxide (29.4 mg/1mL)LotionTopicalJohnson & Johnson Consumer Inc.2019-03-01Not applicableUS flag
Aveeno Anti-itch LotionFerric oxide (3.0 %) + Pramoxine hydrochloride (1.0 %) + Zinc oxide (3.0 %)LotionTopicalJohnson & Johnson2000-05-01Not applicableCanada flag
Aveeno Calamine and Pramoxine Hydrochloride Anti ItchFerric oxide (0.6 mg/1g) + Pramoxine hydrochloride (10 mg/1g) + Zinc oxide (29.4 mg/1g)CreamTopicalJohnson & Johnson Consumer Inc.2013-06-202023-12-01US flag
Baby Anti Monkey Butt Diaper RashFerric oxide (0.02 g/1g) + Zinc oxide (0.12 g/1g)CreamTopicalClarion Brands, Llc2016-03-01Not applicableUS flag
Baby Anti Monkey Butt Diaper RashFerric oxide (0.004 g/1g) + Zinc oxide (0.076 g/1g)PowderTopicalDse Healthcare Solutions, Llc.2012-04-182014-10-14US flag
Baby Anti Monkey Butt Diaper RashFerric oxide (0.004 g/1g) + Zinc oxide (0.076 g/1g)PowderTopicalDse Healthcare Solutions, Llc.2010-05-012012-04-16US flag

Categories

ATC Codes
V08CB03 — Iron oxide, nanoparticles
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as transition metal oxides. These are inorganic compounds containing an oxygen atom of an oxidation state of -2, in which the heaviest atom bonded to the oxygen is a transition metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Transition metal organides
Sub Class
Transition metal oxides
Direct Parent
Transition metal oxides
Alternative Parents
Inorganic salts / Inorganic oxides
Substituents
Inorganic oxide / Inorganic salt / Transition metal oxide
Molecular Framework
Not Available
External Descriptors
iron oxide (CHEBI:50819)
Affected organisms
Not Available

Chemical Identifiers

UNII
1K09F3G675
CAS number
1309-37-1
InChI Key
JEIPFZHSYJVQDO-UHFFFAOYSA-N
InChI
InChI=1S/2Fe.3O
IUPAC Name
oxo[(oxoferrio)oxy]iron
SMILES
O=[Fe]O[Fe]=O

References

General References
Not Available
KEGG Drug
D04168
KEGG Compound
C19424
ChemSpider
452497
RxNav
1310572
ChEBI
50819
Wikipedia
Iron(III)_oxide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedDiagnosticMalignant Neoplasm of Pancreas1
4CompletedTreatmentMelasma1
2CompletedTreatmentHyperphosphataemia1
1CompletedDiagnosticMagnetic Resonance Imaging (MRI)1
1Not Yet RecruitingDiagnosticChronic Kidney Disease (CKD)1
1Not Yet RecruitingDiagnosticCoronary Heart Disease (CHD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CreamTopical
PowderTopical
SuspensionTopical
Aerosol, sprayTopical
OintmentTopical
LiquidTopical
OintmentRectal; Topical
DressingTopical
LotionCutaneous
PasteTopical
LotionTopical
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP0.37ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.37 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity4.24 m3·mol-1ChemAxon
Polarizability7.03 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at April 12, 2016 03:00 / Updated at September 28, 2021 21:54